Skip Main Navigation
Feature

Assay could help guide lung cancer treatment

Non-small cell lung cancer, CT/PET scan - Copyright: Elsevier While surgical resection is an important procedure in treating early stage non-small-cell lung cancer (NSCLC), it is not currently possible to predict disease recurrence. In an Article, Jablons and colleagues report the use of a practical molecular assay which could better identify patients at greater risk of NSCLC recurrence than conventional disease staging. The assay—which analyses the activity of 14 genes in tumour tissue—was validated in NSCLC trials in the USA and China. The study is discussed in a podcast.
Selected Online First articles from The Lancet journals ahead of print publication.
Community based management of severe pneumonia - Copyright: Panos
Community based management of severe pneumonia
Soofi and colleagues report the effectiveness of community based management of severe pneumonia with oral amoxicillin in children in rural Pakistan.
Article The Lancet (online January 27)
Colon cancer - Copyright: Science Photo Library
NICE declines drugs for metastatic colorectal cancer
The latest NICE guidance has declared that bevacizumab, cetuximab, and panitumumab are not cost effective for patients with metastatic colorectal cancer after first-line therapy.
News The Lancet Oncology (online January 25)
Human embryonic stem cell - Copyright: Science Photo Library
Human embryonic stem cells for macular degeneration
Schwartz and colleagues report the use of human embryonic stem cells to treat macular degeneration. It is the first report of the use of such cells in humans for any purpose.
Article The Lancet (online January 23)
  • Device regulation in the European Union: response from MHRA
    Correspondence The Lancet (online January 27)
  • Stereotactic body radiation therapy for management of spinal metastases in patients without spinal cord compression: a phase 1–2 trial
    Article The Lancet Oncology (online January 27)
  • How the Health and Social Care Bill 2011 would end entitlement to comprehensive health care in England
    Comment The Lancet (online January 26)
  • Erlotinib versus chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
    Article The Lancet Oncology (online January 26)
  • NICE guidance on rituximab for first-line treatment of symptomatic stage III-IV lymphoma in previously untreated patients
    News The Lancet Oncology (online January 25)
  • Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial
    Article The Lancet (online January 24)
The Lancet's summary of news and developments across medicine
This Week in Medicine represents a snapshot of important, interesting, and sometimes quirky health-related happenings from around the world reported in the past week or so. This up-to-date content is free to all our users.
Making the most of evaluation

Papers published on The Lancet UK Policy Matters microsite raise concerns about the quality of past evaluations commissioned directly or indirectly by the Department of Health. Read the papers and accompanying blog post to find out more.

About UK Policy Matters

UK Policy Matters is a Lancet-based project which explores how UK policy changes affect health. On our microsite you will be able to access evidence-based summaries of different policies and tell us your experiences of how changes in policy have affected health.

How can you help?

If you have evidence of how policy has affected health or health care, we would like to hear from you. We are interested in all forms of evidence, including brief summaries of evidence from academics; and information from the public, managers, and healthcare workers about changes in services and their impact (individual experiences are welcomed).

See the Submit your evidence section of the site to share your experiences and submit your evidence.

Most read in The Lancet journals in December 2011
1. Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20 536 high-risk individuals: a randomised controlled trial
Article (2011) The Lancet 378 (9808), pp. 2013-2020
2. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
Article (2012) The Lancet Infectious Diseases 12 (1), pp. 36-44
3. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial
Article (2011) The Lancet 378 (9809), pp. 2081-2087
4. Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data
Article (2011) The Lancet Online December 1, 2011
5. The plight of nuns: hazards of nulliparity
Comment (2011) The Lancet Online December 8, 2011
Most cited in The Lancet since 1996
1. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
Research (1998) Lancet 352 (9131), pp. 837-853
2. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: A randomised placebo-controlled trial
Research (2002) Lancet 360 (9326), pp. 7-22
3. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial
Research (1998) Lancet 351 (9118), pp. 1755-1762
4. Peginterferon alfa-2b plus ribavirin compared with interferonalfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial
Research (2001) Lancet 358 (9286), pp. 958-965
5. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
Research (1996) Lancet 348 (9038), pp. 1329-1339